Key Highlights

  • 9.2 million is the USD market Capitalization of SurgePays, Inc. (NASDAQ:SURG) in the screener data, the biggest among five nano-caps, versus 8.33 million for Vistagen and 4.06 million for Arrive AI.
  • 0.07 is the per-share loss forecast for SurgePays, versus -0.37 for Vistagen Therapeutics, Inc. (NASDAQ:VTGN), -3.84 for Arrive AI and -614.25 for Jaguar Health, according to the screener data, before November 13, 2026.
  • 31.7 million is the USD in cash plus securities Vistagen held on June 30, 2026, set against a USD 8.33 million valuation, while Moving iMage Technologies, Inc. (NYSEAMERICAN:MITQ) had USD 3.2 million of net cash and zero debt.
  • 15.68 is the USD loss per share Jaguar Health, Inc. (NASDAQ:JAGX) booked for the second quarter, versus 0.28 lost at Arrive AI Inc. (NASDAQ:ARAI) before its 1-for-48 reverse split effective November 12, 2026, about 13.44 split-adjusted, calculated.

SurgePays, Inc. (NASDAQ:SURG): EPS Estimate -0.07, USD 9.2 Million Market Value

SurgePays, Inc. (NASDAQ:SURG) is scheduled to publish third quarter 2026 results ahead of the opening bell on November 13, 2026, and its call time did not surface in published reporting. The consensus forecast in the screener data calls for a 0.07 loss per share, whereas the second quarter delivered a 0.05 profit for each share, and the USD 9.2 million valuation sits in nano-cap territory. Revenue for the second quarter was USD 16.2 million, a gain of 40.7% from USD 11.5 million, and USD 1.29 million of Net Income followed, aided by an USD 8.5 million gain from a contract settlement. At SurgePays, Inc. (NASDAQ:SURG), the net loss over six months was USD 10.76 million, while USD 1.91 million went to interest expense plus discount amortization. In October 2025 management reaffirmed USD 225 million of 2026 revenue guidance, although second quarter revenue points to a far slower pace. Related filings contain going-concern wording plus a USD 100 million shelf registration.

Vistagen Therapeutics, Inc. (NASDAQ:VTGN): EPS Estimate -0.37, USD 8.33 Million Market Value

Vistagen Therapeutics (NASDAQ:VTGN) publishes fiscal second quarter 2027 results for the three months ending September 30, 2026, ahead of the opening bell on November 13, 2026, with a consensus forecast of a 0.37 loss per share, according to the screener data. The USD 8.33 million valuation, in nano-cap territory, implies a price near USD 0.19 per share over 44.38 million shares outstanding, calculated, and carries a flag as unusual. The previous quarter's loss was USD 0.30 for each share on a USD 13.0 million net loss, versus USD 0.47 and USD 15.1 million one year earlier. At Vistagen Therapeutics, Inc. (NASDAQ:VTGN), revenue was USD 1.48 million, chiefly USD 1.2 million recognized once the Fuji Pharma exclusivity period lapsed. Cash is projected to carry operations into 2027, while the PALISADE-4 trial fell short on its primary endpoint across the overall population. Management expects research outlays to keep declining, depending on what the FDA says about fasedienol, with no numeric guidance in sight.

Jaguar Health, Inc. (NASDAQ:JAGX): EPS Estimate -614.25, USD 6.44 Million Market Value

Jaguar Health (NASDAQ:JAGX) carries the most extreme forecast among these names, a loss of 614.25 for every share in the screener data, a number company releases leave unexplained, with results due once trading ends on November 13, 2026. The USD 6.44 million valuation brings nano-cap hazards. The second quarter produced a loss of USD 15.68 per share, against 358.94 a year before, on revenue of USD 1.225 million, a drop of 59%. At Jaguar Health, Inc. (NASDAQ:JAGX), the operating loss shrank to USD 7.597 million from USD 8.007 million, and selling and Marketing costs dropped to roughly USD 5 thousand once the sales team was disbanded on January 12, 2026. Management expects to file the MVID application for crofelemer, a new drug, in the second three months of 2027. Balances for cash and Debt did not surface in published reporting, with no numerical financial outlook either. The Future Pak and Woodward licensing arrangement delivered USD 16 million upfront during the first quarter, while deferred revenue came to USD 468 thousand.

Moving iMage Technologies, Inc. (NYSEAMERICAN:MITQ): No EPS Estimate, USD 4.98 Million Market Value

Moving iMage Technologies, Inc. (NYSEAMERICAN:MITQ) publishes fiscal first quarter 2027 results for the three months ending September 30, 2026, ahead of the opening bell on November 13, 2026, and the screener data shows no EPS forecast. Its USD 4.98 million valuation, in nano-cap territory, sits under the USD 5.03 million of Gross Profit for fiscal 2026, a calculated comparison. Management guided toward USD 4.5 million of first quarter revenue, compared with USD 5.582 million and USD 509 thousand of net income one year earlier. At Moving iMage Technologies, Inc. (NYSEAMERICAN:MITQ), net sales for fiscal 2026 were USD 17.3 million, a decline of 4.6%, with a gross Margin of 29.1% alongside a net loss near USD 0.30 million. Fourth quarter revenue was USD 4.55 million against USD 5.88 million, which management blamed on projects sliding into later quarters. Net cash was USD 3.2 million with zero debt, and key risks are spending on cinema equipment plus thin liquidity.

Arrive AI Inc. (NASDAQ:ARAI): EPS Estimate -3.84, USD 4.06 Million Market Value

Arrive AI Inc. (NASDAQ:ARAI) is the tiniest name here at USD 4.06 million in the screener data, which is nano-cap territory, and publishes ahead of the opening bell on November 13, 2026, hosting a call at 8:30 a.m. ET. The consensus forecast is a 3.84 loss per share, and what it rests on is unclear since the 1-for-48 reverse split became effective on November 12, 2026. At Arrive AI Inc. (NASDAQ:ARAI), the quarterly net loss for the second quarter was USD 14.08 million, including a USD 9.70 million non-cash loss from converting notes, on revenue of merely USD 14,700. Cash totalled USD 2.98 million on June 30, 2026, along with USD 2.16 million in investments, versus a USD 3.46 million net balance of convertible notes. Stockholders' Equity of USD 4.74 million topped the valuation, a calculated comparison. No numerical guidance appeared, yet management aims for an AP4 launch in early 2027's first quarter, and dilution plus listing compliance bring risk.

Where Things Stand

Five nano-cap companies publish on November 13, 2026, with valuations between USD 4.06 million and USD 9.2 million. SurgePays, Inc. (NASDAQ:SURG) relies upon a settlement gain. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) holds Liquid assets above its valuation. Jaguar Health, Inc. (NASDAQ:JAGX) carries an unexplained forecast in the data. Moving iMage Technologies, Inc. (NYSEAMERICAN:MITQ) guides toward USD 4.5 million of revenue. Arrive AI Inc. (NASDAQ:ARAI) has only just finished a reverse split. Nano-cap shares can swing sharply and trade thinly. Readers should view this piece as general information and not as a recommendation to buy or sell.